Clinical Trials Browser

Interventional × Squamous Cell Carcinoma of Head and Neck × olaparib × Clear all

Squamous Cell Carcinoma of Head and Neck

NCT05366166 2026-01-28

Pembrolizumab Plus Olaparib in LA-HNSCC

Phase 2 Active not recruiting

45 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04643379 2025-10-22

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Phase 2 Active not recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02308072 2024-05-08

ORCA-2

Phase 1 Active not recruiting

70 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03022409 2021-08-10

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Phase 1 Completed

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02882308 2020-02-07

OPHELIA

Phase 2 Completed

41 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02686008 2020-01-13

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01758731 2019-09-23

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

Phase 1 Completed

17 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Smoking

Clinical Trials

A Dye for the Detection of Cancer of the Tongue and Mouth

Pembrolizumab Plus Olaparib in LA-HNSCC

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

ORCA-2

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

OPHELIA

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History